JaulimA,AhmedB,KhanamT,ChatziralliIP, 2013.Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature,Retina 33 901 -91
HahnP,FekratS., 2012.Best practices for treatment of retinal vein occlusion,Curr Opin Ophthalmol 23 175 -81
KolarP, 2014.Risk factors for central and branch retinal vein occlusion: A meta-analysis of published clinical data,J Ophthalmol 724 -80
SchachatAP,WilkinsonCP,HintonDR,SaddaSR,WicdermannP, 2018.Branch retinal vein occlusion,In: Ryan's Retina, ed. 6th. Elsevier 1155 -65
TanMH,McAllisterIL,GilliesME,VermaN,BanerjeeG, 2014.Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion,Am J Ophthalmol 157 237 -47
LeeWJ,KangMH,SeongM,ChoHY, 2012.Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinalvein occlusion,Br J Ophthalmol 96 1426 -30
NomaH,FunatsuH,YamasakiM., 2008.Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion,Graefes Arch Clin Exp Ophthalmol 244 309 -15
HikichiT,HiguchiM,MatsushitaT, 2014.Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion,Br J Ophthalmol 98 195 -9
DonatiS,BaroslP,BianchiM., 2012.Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion,Eur J Ophthalmol 22 607 -14
GabrieleML,WollsteinG,IshikawaH, 2011.Optical coherence tomography: history, current status, and laboratory work,Invest Ophthalmol Vis Sci 52 2425 -36
SpaideRF,LeeJK,KlancnikJK, 2003.Optical coherence tomography of branch retinal vein occlusion,Retina 23 343 -7
MitchellP,SmithW,ChangA, 1996.Prevalence and associations of retinal vein occlusion in Australia. The blue mountains eye study,Arch Ophthalmol 114 1243 -7
KumagaiK., 2014.Three-dimensional optical coherence tomography evaluation of vascular changes at arteriovenous crossings,Retina 55 1867 -75
BatesDO, 2010.Vascular endothelial growth factors and vascular permeability,Cardiovasc Res 87 262 -87
ParkSP,AhnJK, 2009.Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion,Clin Exp Ophthalmol 37 490 -5
JaislleGB,LeitritzM, 2009.One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion,Graefes Arch Clin Exp Ophthalmol 247 27 -33
KornhauserT,SchwartzR,GoldsteinM,NeudorferM,LoewensteinA,BarakA, 2016.Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up),Graefes Arch Clin Exp Ophthalmol 254 835 -44
WuL,ArevaloJF,BerrocalMH, 2009.Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months,Retina 29 1396 -403
AhnSJ,AhnJ,WooSJ,ParkKH, 2013.Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion,BioMed Res Int 209735 -
PaiSA,ShettyR,VijayanPB, 2007.Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion,Am J Ophthalmol 143 601 -6
NoritatasuY,AkitakaT,AtsushiS., 2009.Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion,Retina 29 757 -67
SherifE., 2008.Intravitreal bevacizumab treatment for macular edema secondary to central and branch retinal vein occlusion,J Egypt Ophthalmol Soc 1 73 -8